New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells

Journal of Immunotherapy

Volumn 30, Issue 6, 2007, Pages 607-613

  Du, Xing ^a   Ho, Mitchell ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody scFv; Cytotoxicity; Hematologic malignancies; IL 3 receptor; Pseudomonas exotoxin

Indexed keywords

CD123 ANTIGEN; EPITOPE; IMMUNOTOXIN; INTERLEUKIN 3 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 26292; MONOCLONAL ANTIBODY 32716; PSEUDOMONAS EXOTOXIN A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PSEUDOMONAS; RNA EXTRACTION; SEQUENCE ANALYSIS;

ACUTE DISEASE; ADP RIBOSE TRANSFERASES; ANTIBODIES, MONOCLONAL; BACTERIAL TOXINS; CELL LINE, TUMOR; EXOTOXINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID; RECEPTORS, INTERLEUKIN-3; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

EID: 34547729633     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318053ed8e     Document Type: Article

References (41)

1. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6:559-565.
2. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636.
3. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
4. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937-3942.
5. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23:6719-6729.
6. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology. Am Soc Hematol Educ Program. 2003;82-101.
7. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med. 2000;247:521-534.
8. Suarez L, Vidriales MB, Moreno MJ, et al. Differences in antiapoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica. 2005;90:54-59.
9. Schaich M, Soucek S, Thiede C, et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukemia. Br J Haematol. 2005;128:324-332.
10. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
11. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738-743.
12. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004;23:7178-7187.
13. Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60:4403-4411.
14. Moretti S, Lanza F, Dabusti M, et al. CD123 (interleukin 3 receptor alpha chain). J Biol Regul Homeost Agents. 2001;15:98-100.
15. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
16. Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261-1269.
17. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3R alpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980-2988.
18. Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol. 2004;72:89-106.
19. Testa U, Riccioni R, Diverio D, et al. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18:219-226.
20. Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma. 2006;47:207-222.
21. Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000;14:576-585.
22. Alexander RL, Kucera GL, Klein B, et al. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjug Chem. 2000;11:564-568.
23. Alexander RL, Ramage J, Kucera GL, et al. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 2001;25:875-881.
24. Feuring-Buske M, Frankel AE, Alexander RL, et al. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002;62:1730-1736.
25. Testa U, Riccioni R, Biffoni M, et al. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood. 2005;106:2527-2529.
26. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol. 2004;248:503-518.
27. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000;6:1476-1487.
28. Nagata S, Onda M, Numata Y, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res. 2002;8:2345-2355.
29. Pannu KK, Joe ET, Iyer SB. Performance evaluation of Quanti-BRITE phycoerythrin beads. Cytometry. 2001;45:250-258.
30. Reiter Y, Brinkmann U, Lee B, et al. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol. 1996;14:1239-1245.
31. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J. 1995;307:29-37.
32. Seetharam S, Chaudhary VK, FitzGerald D, et al. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem. 1991;266:17376-17381.
33. Batra JK, Fitzgerald DJ, Chaudhary VK, et al. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol. 1991;11:2200-2205.
34. Hogge DE, Willman CL, Kreitman RJ, et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1998;92:589-595.
35. Hogge DE, Yalcintepe L, Wong SH, et al. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res. 2006;12:1284-1291.
36. Yalcintepe L, Frankel AE, Hogge D. Expression of Interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors which engraft in immunodeficient mice. Blood. 2006;108:3530-3537.
37. Korpelainen EI, Gamble JR, Vadas MA, et al. IL3 receptor expression, regulation and function in cells of the vasculature. Immunol Cell Biol. 1996;74:1-7.
38. Morikawa Y, Tohya K, Hara T, et al. Expression of IL3 receptor in testis. Biochem Biophys Res Commun. 1996;226:107-112.
39. Tabira T, Chui DH, Fan JP, et al. Interleukin-3 and interleukin-3 receptors in the brain. Ann NY Acad Sci. 1998;840:107-116.
40. Cohen KA, Liu TF, Cline JM, et al. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma. 2004;45:1647-1656.
41. Cohen KA, Liu TF, Cline JM, et al. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005;54:799-806.